August 29, 2026 – Patient Worthy

Orsini Selected as Specialty Pharmacy Partner for Newly Approved Dermatomyositis Therapy LISRAYA

Post author:Austin Newman
Post published:August 29, 2026
Post category:Dermatomyositis

As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the US Food and Drug Administration…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More